An early observation suggests that children older than 6 years of age at diagnosis of neuroblastoma constitute a favorable prognostic group.
Kaplan-Meier plots of survival of all such patients diagnosed at the Children's Hospital of Pittsburgh 1975-1992 were compared with curves of concurrently treated patients with Stage IV disease who were 1-6 years of age at diagnosis ( « younger patients »). Known prognostic features, including stage and primary site of disease, pattern of metastases, histopathology, MYCN gene amplification, and urinary catecholamine metabolite ratios, were reviewed.
Of 17 children diagnosed after the age of 6 years ( « older patients »), 13 patients had Evans'Stage IV disease and 4 had Stage III disease.
The median survival was 3.24 years (range, 0.63-15.04 years) for the entire cohort and 3.07 years for those children with Stage IV disease.
Older children with neuroblastoma have a more indolent course than do younger patients, a finding that appears to be related to favorable histology and the absence of MYCN amplification.
Examination of larger numbers of such patients from cooperative groups should lead to a better understanding of what appears to be a subset of pediatric patients with neuroblastoma who may benefit from specifically tailored treatment protocols.
Mots-clés Pascal : Neuroblastome, Enfant, Homme, Age, Stade avancé, Pronostic, Survie, Etude cohorte, Gène onc cellulaire, Système nerveux pathologie, Système nerveux sympathique pathologie, Tumeur maligne, Gène myc
Mots-clés Pascal anglais : Neuroblastoma, Child, Human, Age, Advanced stage, Prognosis, Survival, Cohort study, C-Onc gene, Nervous system diseases, Autonomic neuropathy, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0498996
Code Inist : 002B17E. Création : 01/03/1996.